Retatrutide and Relationships

    By Trimi Medical Team11 min read

    Losing 20-24% of body weight on retatrutide (Jastreboff et al., NEJM 2023) changes more than your body. It reshapes relationships in ways that can be wonderful, challenging, and unexpected. From romantic partnerships to friendships to family dynamics, understanding common patterns helps patients and their loved ones navigate the transformation together.

    Medical Disclaimer: This article is for informational purposes only. Retatrutide is an investigational drug not yet approved by the FDA. If relationship stress becomes overwhelming, consider couples therapy or individual counseling.

    Romantic Relationships

    Major weight loss can strengthen or strain romantic partnerships. Positive changes often include increased physical confidence and intimacy, more shared physical activities, improved mood and energy for quality time, and a partner's pride in your health improvements. Challenges may include a partner feeling threatened by your transformation or increased attention from others, shifting power dynamics as confidence grows, less bonding over shared meals (a common couples ritual), jealousy or insecurity in either partner, and differing views on medication-assisted weight loss.

    Communication is essential. Talk with your partner about changes you are experiencing, include them in your health journey when possible, reassure them that your commitment has not changed, and seek couples counseling if conflicts intensify.

    Friendships

    Friendships built around food-centered activities may shift. Friends may feel uncomfortable eating around you, assume you are judging their food choices, feel left behind if they also struggle with weight, or drift away as lifestyles diverge. Other friends may become more supportive, ask for advice about their own weight, or want to join you in new activities. The friendships that survive and strengthen are typically those based on genuine connection beyond food and body size.

    Family Dynamics

    Family responses to dramatic weight loss are complex. Parents may express concern about medication safety, especially if they grew up with different views on weight management. Siblings may feel competitive or jealous. Children benefit from seeing a healthier, more active parent. Extended family may make well-meaning but insensitive comments about your appearance.

    Strategies for navigating family dynamics include setting boundaries around diet and body talk, educating family members about obesity as a medical condition, focusing conversation on health improvements rather than appearance, and being patient with family members who need time to adjust.

    Food and Social Life

    Food is central to social connection in most cultures. Retatrutide's appetite suppression and GI effects can make social eating challenging. Restaurant meals may cause nausea if portions are too large. Alcohol tolerance often decreases. Declining food can feel socially awkward. Holiday and celebration meals become complicated.

    Practical approaches include eating a small amount before events to avoid being empty-stomached, ordering appetizers or sides as your main course, focusing on the social connection rather than the food, being honest with close friends about your medication and dietary needs, and suggesting non-food-centered activities.

    The Dating World After Weight Loss

    For single patients, weight loss can transform the dating experience. Increased confidence often leads to more social engagement. However, some patients struggle with trust (do they like me or my new body?), dating anxiety from years of body-image-related avoidance, and complex feelings about being valued differently based on appearance. These experiences are common and processing them, ideally with a therapist, supports healthier relationships.

    GLP-1 Treatment That Supports Your Life

    Trimi offers compounded semaglutide ($99/month) and compounded tirzepatide ($125/month) with medical teams who understand that weight loss transforms every aspect of life. Learn how Trimi works.

    Frequently Asked Questions

    Will weight loss save my relationship?

    Weight loss can improve relationship dynamics by increasing confidence, energy, and physical capacity, but it cannot fix fundamental relationship issues. Couples with strong foundations typically grow stronger; those with existing problems may see them amplified.

    My partner is not supportive of my medication. What should I do?

    Educate them about obesity as a medical condition and GLP-1 medications as evidence-based treatment. Invite them to a medical appointment. If resistance persists, couples counseling can help address underlying concerns.

    How do I handle food-centered social events?

    Plan ahead: eat a small snack beforehand, choose menu items you can tolerate, focus on the social aspects, and be comfortable saying "I am not very hungry tonight." Most people will not question it.

    My friends treat me differently since losing weight. Is this normal?

    Yes. Changed treatment from others is one of the most commonly reported experiences after major weight loss. It can bring up complex emotions about being valued based on appearance. Therapy can help process these feelings.

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    Related Reading

    What does the published clinical evidence show for retatrutide?

    Peer-reviewed evidence: Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023). Trimi is preparing for launch; compounded availability depends on FDA-cleared compounding pathways. Results vary by individual; eligibility is determined by a licensed clinician.

    Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. — Jastreboff et al. Phase 2 trial, NEJM 2023
    Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. — Rosenstock et al. Phase 2 T2D trial, Lancet 2023

    Key Takeaways

    • Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023)
    • Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. (Source: Rosenstock et al. Phase 2 T2D trial, Lancet 2023)
    • Retatrutide is investigational and not FDA-approved as of publication. Trial findings reported here are from Phase 2 / Phase 3 studies in peer-reviewed sources cited below.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: June 2, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    It's only been 2 weeks since I've been taking the VialsRx meds from Trimi. The medication showed up pretty quickly (about 4 days after getting approval from Trimi prescriber) and I received 3 vials for my first 3 months on the subscription. For the price and convenience my take is that Trimi and VialsRx is good.

    Outcome: 4-day delivery; 3 vials for first 3 months; price + convenience verdict positive

    Really great customer service! Fast shipment.

    Outcome: Fast shipment

    Amy KeithFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2301972
    2. Rosenstock J, Frias J, Jastreboff AM, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet.Read StudyDOI: 10.1016/S0140-6736(23)01053-X
    3. ClinicalTrials.gov (2024). A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Are Overweight (TRIUMPH-1) — NCT05929066. ClinicalTrials.gov.Read Study
    4. Garvey WT, Mechanick JI, Brett EM, et al. (2024). American Association of Clinical Endocrinology / American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice.Read StudyDOI: 10.4158/EP161365.GL
    5. American Heart Association (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation.Read StudyDOI: 10.1161/CIR.0000000000000973
    6. Apovian CM, Aronne LJ, Bessesen DH, et al. (2015). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism.Read StudyDOI: 10.1210/jc.2014-3415

    Was this article helpful?

    Keep Reading

    Clinician-reviewed Trimi guide to GLP-1: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded GLP-1 option compares to brand alternatives.

    Clinician-reviewed Trimi guide to retatrutide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded retatrutide option compares to brand alternatives.

    Clinician-reviewed Trimi guide to retatrutide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded retatrutide option compares to brand alternatives.

    Clinician-reviewed Trimi guide to GLP-1: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded GLP-1 option compares to brand alternatives.

    Start your GLP-1 journey — from $99/mo

    Get Started